Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Unveiling Significance of Time in Range: Value as key Glycemic Biomarker

Unveiling Significance of Time in Range: Value as key Glycemic Biomarker

Need to redefine the treatment paradigm Post OAD

Need to redefine the treatment paradigm Post OAD

SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy

SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy

The Evolving Role of Treatment and Technology in Diabetes Care

The Evolving Role of Treatment and Technology in Diabetes Care

Time-in-Range: A Key Determinant of Quality of Life

Time-in-Range: A Key Determinant of Quality of Life

The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.

The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.

What Are the Signs and Symptoms of ASMD?

What Are the Signs and Symptoms of ASMD?

An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy

An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy

Gaucher

Gaucher

Better care for Fabry

Better care for Fabry

Every Moment Matters on the Fabry Journey

Navigating the Pompe Disease Journey

Navigating the Pompe Disease Journey

Recognizing Key Signs and Symptoms Along the Way

Glargine 300 use in people with type 2 diabetes who fast during Ramadan

Glargine 300 use in people with type 2 diabetes who fast during Ramadan

Watch Professor Mohamed Hassanein, consultant endocrinologist in Dubai Hospital, Dubai Health Authority and the chair of Diabetes and Ramadan International Alliance shedding the light on what are the unmet needs amongst Muslims with Type 2 diabetes when fast during Ramadan.